CN116322750A - 抗原特异性t细胞受体和嵌合抗原受体以及用于癌症免疫疗法的免疫信号传导调节中的使用方法 - Google Patents

抗原特异性t细胞受体和嵌合抗原受体以及用于癌症免疫疗法的免疫信号传导调节中的使用方法 Download PDF

Info

Publication number
CN116322750A
CN116322750A CN202180056522.1A CN202180056522A CN116322750A CN 116322750 A CN116322750 A CN 116322750A CN 202180056522 A CN202180056522 A CN 202180056522A CN 116322750 A CN116322750 A CN 116322750A
Authority
CN
China
Prior art keywords
tcr
seq
amino acid
polypeptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180056522.1A
Other languages
English (en)
Chinese (zh)
Inventor
王荣福
王羿成
尹冰楠
钱晨
柳鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methodist Hospital
Original Assignee
Methodist Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methodist Hospital filed Critical Methodist Hospital
Publication of CN116322750A publication Critical patent/CN116322750A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180056522.1A 2020-06-25 2021-06-25 抗原特异性t细胞受体和嵌合抗原受体以及用于癌症免疫疗法的免疫信号传导调节中的使用方法 Pending CN116322750A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063044150P 2020-06-25 2020-06-25
US63/044,150 2020-06-25
PCT/US2021/039262 WO2021263211A2 (en) 2020-06-25 2021-06-25 Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy

Publications (1)

Publication Number Publication Date
CN116322750A true CN116322750A (zh) 2023-06-23

Family

ID=79281973

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180056522.1A Pending CN116322750A (zh) 2020-06-25 2021-06-25 抗原特异性t细胞受体和嵌合抗原受体以及用于癌症免疫疗法的免疫信号传导调节中的使用方法

Country Status (7)

Country Link
US (1) US20230250149A1 (https=)
EP (1) EP4171587A4 (https=)
JP (2) JP7781085B2 (https=)
CN (1) CN116322750A (https=)
AU (1) AU2021297458A1 (https=)
CA (1) CA3188143A1 (https=)
WO (1) WO2021263211A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4519675A4 (en) * 2022-05-03 2026-04-08 3T Biosciences Inc T-LYMPHOCYTE TARGET DISCOVERY
KR20250017213A (ko) * 2022-05-25 2025-02-04 고쿠리츠 다이가쿠 호우징 도우카이 고쿠리츠 다이가쿠 기코우 폴리뉴클레오티드
WO2024163292A1 (en) * 2023-01-30 2024-08-08 Board Of Regents, The University Of Texas System T-cell receptors targeting her2 and methods of use thereof
EP4731758A2 (en) * 2023-06-20 2026-04-29 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
WO2024263818A2 (en) * 2023-06-20 2024-12-26 Immunova Therapeutics Llc Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains
WO2025084880A1 (ko) * 2023-10-20 2025-04-24 주식회사 이온셀 Ct83 항원에 결합하는 car-t 세포 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132423A (zh) * 2014-02-14 2016-11-16 贝里坤制药股份有限公司 用诱导型嵌合多肽活化t细胞的方法
CN107106611A (zh) * 2014-10-27 2017-08-29 弗雷德哈钦森癌症研究中心 用于提高过继细胞免疫疗法效力的组合物和方法
CN107667170A (zh) * 2015-06-01 2018-02-06 Ucl商务股份有限公司 细胞

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2899679C (en) * 2013-01-29 2023-03-21 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch High avidity antigen recognizing constructs
CA3051222C (en) * 2013-06-10 2023-01-24 Dana-Farber Cancer Institute, Inc. Methods and compositions for reducing immunosupression by tumor cells
US20170335331A1 (en) * 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
CA2996887A1 (en) * 2015-09-11 2017-03-16 Agenus Inc. Engineered host cells and methods of use thereof
JP2019515656A (ja) * 2016-03-15 2019-06-13 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ キメラ抗原受容体
AU2019224051A1 (en) 2018-02-26 2020-09-03 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
EP3806857A4 (en) * 2018-06-14 2022-03-02 2seventy bio, Inc. CD79A CHIMERIC ANTIGEN RECEPTORS
WO2020086647A1 (en) * 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132423A (zh) * 2014-02-14 2016-11-16 贝里坤制药股份有限公司 用诱导型嵌合多肽活化t细胞的方法
CN107106611A (zh) * 2014-10-27 2017-08-29 弗雷德哈钦森癌症研究中心 用于提高过继细胞免疫疗法效力的组合物和方法
CN107667170A (zh) * 2015-06-01 2018-02-06 Ucl商务股份有限公司 细胞

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOHN A CRADDOCK等: "Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b", J IMMUNOTHER, vol. 33, no. 8, 31 October 2010 (2010-10-31), pages 780 - 788 *
YANGBING ZHAO等: "Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines", THE JOURNAL OF IMMUNOLOGY, 31 December 2005 (2005-12-31), pages 4415 - 4423 *
YANGBING ZHAO等: "Transduction of an HLA-DP4–restricted NY-ESO-1–specific TCR into Primary Human CD4+ Lymphocytes", JOURNAL OF IMMUNOTHERAPY, vol. 29, no. 4, 31 July 2006 (2006-07-31), pages 398 - 406 *
YONGGUI TIAN等: "Gene modification strategies for next-generation CAR T cells against solid cancers", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 13, no. 1, 18 May 2020 (2020-05-18), pages 1 - 16 *

Also Published As

Publication number Publication date
WO2021263211A2 (en) 2021-12-30
AU2021297458A1 (en) 2023-02-02
JP7781085B2 (ja) 2025-12-05
US20230250149A1 (en) 2023-08-10
JP2025166212A (ja) 2025-11-05
WO2021263211A3 (en) 2022-03-10
JP2023532278A (ja) 2023-07-27
EP4171587A4 (en) 2024-07-24
CA3188143A1 (en) 2021-12-30
WO2021263211A9 (en) 2022-02-03
EP4171587A2 (en) 2023-05-03

Similar Documents

Publication Publication Date Title
CN116322750A (zh) 抗原特异性t细胞受体和嵌合抗原受体以及用于癌症免疫疗法的免疫信号传导调节中的使用方法
US12565680B2 (en) Cancer neoantigens and their utilities in cancer vaccines and TCR-based cancer immunotherapy
JP2008508861A5 (https=)
US20220257735A1 (en) A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes
US20240082304A1 (en) Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
WO2024263821A2 (en) Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
WO2022226282A1 (en) Engineering biologics to hpv oncoproteins
ITFI990094A1 (it) Metodo diagnostico per il riconoscimento di neoplasie umane attraverso la determinazione dell'isoforma ctn-c della tn-c,frammenti di
JP2015042641A (ja) 壊死マーカー及びその用途
WO2014179751A1 (en) Compositions and methods for the treatment of human immunodeficiency virus infection
JPH1192401A (ja) ヒト血清グルココルチコイドにより調節されるキナーゼ、慢性腎不全に対する標的
CN114051416A (zh) Gpcr异聚体抑制剂及其用途
HK40092820A (zh) 抗原特异性t细胞受体和嵌合抗原受体以及用於癌症免疫疗法的免疫信号传导调节中的使用方法
CN121002053A (zh) 组织蛋白酶d/lrp-1相互作用的肽抑制剂
WO2024182718A2 (en) Compositions and methods related to transcobalamin receptor autoantibodies
EP3920887B1 (en) A phosphatidylinositol-glycan-specific phospholipase d1 (gpld1) polypeptide for use in a method of treating or preventing age-related cognitive dysfunction
US20250304636A1 (en) Dap12 constructs and their use to enhance dc vaccines and immunotherapies
US20240293460A1 (en) Dkk1/hla-a2 binding molecules and methods of their use
US12209137B2 (en) Antigen binding proteins specifically binding CT45
WO2025171250A1 (en) Nyeso1 tcr for t-cell therapy and methods of use
WO2004016646A2 (en) Peptide modulators of tumour specific pyruvate kinase subtype m2 (m2-pk)
WO2023220542A1 (en) Utilization of immortalized b cells to identify sdcbp as a novel therapeutic target in ovarian carcinoma
JP2008528023A (ja) ウロキナーゼプラスミノーゲンアクチベーター受容体由来の治療ペプチド
KR20170093806A (ko) 항원 제시의 검출 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092820

Country of ref document: HK